Genialis key facts
as of Oct 2026- Developer of an AI-driven cancer biology platform designed to predict how therapies will perform in patients.
- Genialis is valued at approximately $37.0M as of Oct 2026 (last reported valuation).
- It has raised $16.4M across 2 recorded rounds; the latest was Seed Round ($700K) in Dec 2025.
- Notable investors include Redalpine, Rajeev Surati, Debiopharm Innovation Fund, Drew Volpe, First Star Ventures — 9 tracked in total.
- Genialis has filed 1 Form D with the SEC, most recently Jan 2023 ($11.4M sold to 10 investors).
- Status: Privately Held (backing).
Genialis's last reported valuation, Jan 2023. Nothing priced has surfaced since.
- ·Watch Genialis: the Monday email on marks, rounds and moves
Genialis funding rounds
2 roundsGenialis valuation
Genialis's last reported valuation was $37 million in Jan 2023. No priced round, secondary trade or fund mark has surfaced since.
How much has Genialis raised?
Genialis has raised $16.4 million in total; 2 of its rounds are on record. The largest on record was a $700,000 seed round in Dec 2025.
Genialis has filed 1 Form D with the SEC, most recently in Jan 2023 ($11.4 million sold to 10 investors).
Genialis investors
9 investors are on record for Genialis, including Redalpine, Rajeev Surati, Debiopharm Innovation Fund and Drew Volpe. The seed round in Dec 2025 drew 2 investors.
About Genialis
Developer of an AI-driven cancer biology platform designed to predict how therapies will perform in patients. The company offers an RNA-based foundation model trained on large-scale tumor data, enabling pharmaceutical developers, diagnostics teams, and clinicians to evaluate drug behavior, improve test development, and support more informed treatment decisions.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Employees
- 25
- Website
- genialis.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.